Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Rocha, Cheila ^a,b   Calado, Rita ^a,b   Borrego, Pedro ^a,b   Marcelino, José M ^c   Bártolo, Inês ^a,b   Rosado, Lino ^d   Cavaco Silva, Patrícia ^b   Gomes, Perpétua ^b,e,f   Família, Carlos ^b   Quintas, Alexandre ^b   Skar, Helena ^g   Leitner, Thomas ^g   Barroso, Helena ^a,b   Taveira, Nuno ^a,b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^d HOSPITAL DONA ESTEFÂNIA   (Portugal)

^e Centro Hospitalar Lisboa Ocidental   (Portugal)

^f Instututo de Higiene e Medicina Tropical   (Portugal)

^g LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Escape from neutralization; Evolution of the neutralizing antibody response; Molecular evolution; Tropism; Vertical HIV 2 infection

Indexed keywords

ABACAVIR; AMINO ACID; CD4 ANTIGEN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEUTRALIZING ANTIBODY; NUCLEOTIDE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CHILD; DISEASE COURSE; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MALE; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE; SCHOOL CHILD; VIRAL TROPISM; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

ANTIBODIES, NEUTRALIZING; ANTIGENIC VARIATION; CHILD; CHILD, PRESCHOOL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; FEMALE; GENETIC VARIATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-2; HUMANS; INFANT; INFANT, NEWBORN; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA;

EID: 84885972003     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-110     Document Type: Article

References (74)

1. De Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol 2008, 16:588-595. 10.1016/j.tim.2008.09.003, 18964021.
2. Gottlieb GS, Eholie SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, Sow PS. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008, 22:2069-2072. discussion 2073-2064, 10.1097/QAD.0b013e32830edd44, 2635911, 18832869.
3. Yamaguchi J, Devare SG, Brennan CA. Identification of a new HIV-2 subtype based on phylogenetic analysis of full-length genomic sequence. AIDS Res Hum Retroviruses 2000, 16:925-930. 10.1089/08892220050042864, 10875618.
4. Damond F, Worobey M, Campa P, Farfara I, Colin G, Matheron S, Brun-Vezinet F, Robertson DL, Simon F. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 2004, 20:666-672. 10.1089/0889222041217392, 15242544.
5. van der Loeff MF S, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, Alabi A, Bayang A, Ariyoshi K, Whittle HC. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002, 16:1775-1783. 10.1097/00002030-200209060-00010, 12218389.
6. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011, 52:780-787. 10.1093/cid/ciq248, 3106263, 21367732.
7. Matheron S, Pueyo S, Damond F, Simon F, Lepretre A, Campa P, Salamon R, Chene G, Brun-Vezinet F. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003, 17:2593-2601. 10.1097/00002030-200312050-00006, 14685053.
8. van der Loeff MF, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, Van Tienen C, Leligdowicz A, Sarge-Njie R, Da Silva Z, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010, 7:46. 10.1186/1742-4690-7-46, 2887382, 20482865.
9. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998, 1:457-468.
10. Jaffar S, Wilkins A, Ngom PT, Sabally S, Corrah T, Bangali JE, Rolfe M, Whittle HC. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:327-332. 10.1097/00042560-199712150-00003, 9420309.
11. Lisse IM, Poulsen AG, Aaby P, Knudsen K, Dias F. Serial CD4 and CD8 T-lymphocyte counts and associated mortality in an HIV-2-infected population in Guinea-Bissau. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:355-362. 10.1097/00042560-199612010-00009, 8948374.
12. Popper SJ, Sarr AD, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol 2000, 74:1554-1557. 10.1128/JVI.74.3.1554-1557.2000, 111493, 10627569.
13. Andersson S, Norrgren H, Da Silva Z, Biague A, Bamba S, Kwok S, Christopherson C, Biberfeld G, Albert J. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000, 160:3286-3293. 10.1001/archinte.160.21.3286, 11088091.
14. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265:1587-1590. 10.1126/science.7915856, 7915856.
15. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, Dabis F, Brun-Vezinet F, Chene G, Thiebaut R. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008, 22:457-468. 10.1097/QAD.0b013e3282f4ddfc, 2727618, 18301058.
16. Marcelino JM, Nilsson C, Barroso H, Gomes P, Borrego P, Maltez F, Rosado L, Doroana M, Antunes F, Taveira N. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. AIDS 2008, 22:2257-2265. 10.1097/QAD.0b013e3283155546, 18981765.
17. Rodriguez SK, Sarr AD, MacNeil A, Thakore-Meloni S, Gueye-Ndiaye A, Traore I, Dia MC, Mboup S, Kanki PJ. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J Virol 2007, 81:5331-5338. 10.1128/JVI.02789-06, 1900200, 17301136.
18. Ozkaya Sahin G, Holmgren B, Da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjornsson J, Mansson F, Andersson S, Norrgren H, Aaby P, et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol 2012, 86:961-971. 10.1128/JVI.06315-11, 3255861, 22072782.
19. De Silva TI, Aasa-Chapman M, Cotten M, Hue S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 2012, 86:930-946. 10.1128/JVI.06126-11, 3255814, 22072758.
20. Bjorling E, Scarlatti G, Von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, Norrby E, Fenyo EM. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993, 193:528-530. 10.1006/viro.1993.1160, 8438591.
21. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 2012, 86:947-960. 10.1128/JVI.06155-11, 3255805, 22031948.
22. Borrego P, Calado R, Marcelino JM, Bartolo I, Rocha C, Cavaco-Silva P, Doroana M, Antunes F, Maltez F, Caixas U, et al. Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther 2012, 17(3):565-570. 10.3851/IMP1996, 22293827.
23. Marcelino JM, Borrego P, Nilsson C, Familia C, Barroso H, Maltez F, Doroana M, Antunes F, Quintas A, Taveira N. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. AIDS 2012, 26:2275-2284. 10.1097/QAD.0b013e328359a89d, 23151495.
24. Skar H, Borrego P, Wallstrom TC, Mild M, Marcelino JM, Barroso H, Taveira N, Leitner T, Albert J. HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. J Virol 2010, 84:7412-7415. 10.1128/JVI.02548-09, 2898231, 20463072.
25. Borrego P, Marcelino JM, Rocha C, Doroana M, Antunes F, Maltez F, Gomes P, Novo C, Barroso H, Taveira N. The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. Retrovirology 2008, 5:78. 10.1186/1742-4690-5-78, 2563025, 18778482.
26. Bjorling E, Chiodi F, Utter G, Norrby E. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol 1994, 152:1952-1959.
27. Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, et al. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol 2012, 86:12115-12128. 10.1128/JVI.01632-12, 3486499, 22933274.
28. McKnight A, Shotton C, Cordell J, Jones I, Simmons G, Clapham PR. Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol 1996, 70:4598-4606. 190396, 8676486.
29. Skott P, Achour A, Norin M, Thorstensson R, Bjorling E. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2. Viral Immunol 1999, 12:79-88. 10.1089/vim.1999.12.79, 10333245.
30. Barroso H, Araujo F, Gomes MH, Mota-Miranda A, Taveira N. Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthood. AIDS Res Hum Retroviruses 2004, 20:1373-1376. 10.1089/aid.2004.20.1373, 15650432.
31. Cavaco-Silva P, Taveira NC, Lourenco MH, Santos Ferreira MO, Daniels RS. Vertical transmission of HIV-2. Lancet 1997, 349:177-178. 10.1016/S0140-6736(05)60978-6, 9111547.
32. Cavaco-Silva P, Taveira NC, Rosado L, Lourenco MH, Moniz-Pereira J, Douglas NW, Daniels RS, Santos-Ferreira MO. Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission. J Virol 1998, 72:3418-3422. 109839, 9525673.
33. Padua E, Almeida C, Nunes B, Cortes Martins H, Castela J, Neves C, Paixao MT. Assessment of mother-to-child HIV-1 and HIV-2 transmission: an AIDS reference laboratory collaborative study. HIV Med 2009, 10:182-190. 10.1111/j.1468-1293.2008.00669.x, 19207600.
34. Mota-Miranda A, Gomes H, Lima-Alves C, Araujo F, Cunha-Ribeiro LM, Taveira N. Perinatally acquired HIV-2 infection diagnosed at 15 and 24 years of age. AIDS 2001, 15:2460-2461. 10.1097/00002030-200112070-00018, 11826851.
35. Burgard M, Jasseron C, Matheron S, Damond F, Hamrene K, Blanche S, Faye A, Rouzioux C, Warszawski J, Mandelbro L. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French perinatal cohort EPF-CO1. Clin Infect Dis 2010, 51:833-843. 10.1086/656284, 20804413.
36. Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vezinet F, Descamps D. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis 2012, 205:111-120. 10.1093/infdis/jir698, 22140264.
37. Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Brostrom C, Fenyo EM, Albert J. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 2005, 86:3385-3396. 10.1099/vir.0.81259-0, 16298986.
38. Isaka Y, Sato A, Miki S, Kawauchi S, Sakaida H, Hori T, Uchiyama T, Adachi A, Hayami M, Fujiwara T, Yoshie O. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 1999, 264:237-243. 10.1006/viro.1999.0006, 10544150.
39. Bunnik EM, Pisas L, Van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008, 82:7932-7941. 10.1128/JVI.00757-08, 2519599, 18524815.
40. Rey MA, Girard PM, Harzic M, Madjar JJ, Brun-Vezinet F, Saimot AG. HIV-1 and HIV-2 double infection in French homosexual male with AIDS-related complex (Paris, 1985). Lancet 1987, 1:388-389.
41. Matheron S, Mendoza-Sassi G, Simon F, Olivares R, Coulaud JP, Brun-Vezinet F. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997, 11:934-936.
42. Norrgren H, Da Silva Z, Biague A, Andersson S, Biberfeld G. Clinical progression in early and late stages of disease in a cohort of individuals infected with human immunodeficiency virus-2 in Guinea-Bissau. Scand J Infect Dis 2003, 35:265-272. 10.1080/00365540310000210, 12839157.
43. Blaak H, van der Ende ME, Boers PH, Schuitemaker H, Osterhaus AD. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology 2006, 353:144-154. 10.1016/j.virol.2006.05.029, 16814357.
44. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Rainwater SM, Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006, 80:835-844. 10.1128/JVI.80.2.835-844.2006, 1346878, 16378985.
45. Hoffmann FG, He X, West JT, Lemey P, Kankasa C, Wood C. Genetic variation in mother-child acute seroconverter pairs from Zambia. AIDS 2008, 22:817-824. 10.1097/QAD.0b013e3282f486af, 18427199.
46. Zhang H, Tully DC, Hoffmann FG, He J, Kankasa C, Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One 2010, 5:e9294. 10.1371/journal.pone.0009294, 2823783, 20174636.
47. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008, 82:3952-3970. 10.1128/JVI.02660-07, 2293010, 18256145.
48. Zhang H, Hoffmann F, He J, He X, Kankasa C, Ruprecht R, West JT, Orti G, Wood C. Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology 2005, 2:67. 10.1186/1742-4690-2-67, 1308862, 16274482.
49. Zhang H, Hoffmann F, He J, He X, Kankasa C, West JT, Mitchell CD, Ruprecht RM, Orti G, Wood C. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006, 3:73. 10.1186/1742-4690-3-73, 1635063, 17054795.
50. Doria-Rose NA, Georgiev I, O'Dell S, Chuang GY, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 2012, 86:8319-8323. 10.1128/JVI.00696-12, 3421697, 22623764.
51. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005, 102:18514-18519. 10.1073/pnas.0504658102, 1310509, 16339909.
52. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 2009, 5:e1000594. 10.1371/journal.ppat.1000594, 2741593, 19763269.
53. Marcelino JM, Borrego P, Rocha C, Barroso H, Quintas A, Novo C, Taveira N. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J Virol 2010, 84:12429-12436. 10.1128/JVI.01102-10, 2976386, 20844029.
54. Soares R, Foxall R, Albuquerque A, Cortesao C, Garcia M, Victorino RM, Sousa AE. Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection. J Virol 2006, 80:12425-12429. 10.1128/JVI.01557-06, 1676275, 17035326.
55. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al. Clustal W and clustal X version 2.0. Bioinformatics 2007, 23:2947-2948. 10.1093/bioinformatics/btm404, 17846036.
56. SequenceDatabase Los Alamos sequence database 2009, Los Alamos, New Mexico: Los Alamos National Laboratory, http://www.hiv.lanl.gov/, SequenceDatabase.
57. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics 1998, 14:817-818. 10.1093/bioinformatics/14.9.817, 9918953.
58. Swofford DL, Waddell PJ, Huelsenbeck JP, Foster PG, Lewis PO, Rogers JS. Bias in phylogenetic estimation and its relevance to the choice between parsimony and likelihood methods. Syst Biol 2001, 50:525-539.
59. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985, 39:783-791.
60. Lee HY, Perelson AS, Park SC, Leitner T. Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol 2008, 4:e1000240. 10.1371/journal.pcbi.1000240, 2602878, 19079613.
61. Bruen TC, Philippe H, Bryant D. A simple and robust statistical test for detecting the presence of recombination. Genetics 2006, 172:2665-2681. 1456386, 16489234.
62. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 2006, 23:254-267.
63. Pond SL, Frost SD. Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 2005, 21:2531-2533. 10.1093/bioinformatics/bti320, 15713735.
64. Muse SV, Gaut BS. A likelihood approach for comparing synonymous and nonsynonymous nucleotide substitution rates, with application to the chloroplast genome. Mol Biol Evol 1994, 11:715-724.
65. Kosakovsky Pond SL, Frost SD. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 2005, 22:1208-1222. 10.1093/molbev/msi105, 15703242.
66. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 2007, 7:214. 10.1186/1471-2148-7-214, 2247476, 17996036.
67. Shapiro B, Rambaut A, Drummond AJ. Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences. Mol Biol Evol 2006, 23:7-9.
68. Rambaut A, Drummond AJ. Tracer v1.4 2007, Available from http://beast.bio.ed.ac.uk/Tracer.
69. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, Korber B. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14:1229-1246. 10.1093/glycob/cwh106, 15175256.
70. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R, Wolinsky SM. Genetic differences between blood-and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 1994, 68:7467-7481. 237189, 7933130.
71. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312. 10.1038/nature01470, 12646921.
72. GraphPad Graph pad software Inc.: Prism 5, version 5.04 2010, GraphPad.
73. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201. 10.1093/bioinformatics/bti770, 16301204.
74. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003, 31:3381-3385. 10.1093/nar/gkg520, 168927, 12824332.